. 2023 Nov 30;6(11):e2345138. doi: 10.1001/jamanetworkopen.2023.45138

Table 2. Primary and Secondary Efficacy Outcomes in the Intention-to-Treat Analysis.

Outcomes	Participants, No./Total No. (%)		RR (95% CI)^a	P value^b
Outcomes	SA group	NSA group	RR (95% CI)^a	P value^b
Primary outcome, depression recovery at 3 mo vs baseline (n = 47)^c^,^d	14/24 (58)	10/23 (43)	1.34 (0.76-2.45)	.38
Secondary outcomes
Depression recovery at 4 wk vs baseline (n = 57)	12/28 (43)	9/29 (31)	1.28 (0.74-2.14)	.42
Depression recovery at 6 wk vs baseline (n = 51)	10/26 (38)	10/25 (40)	0.96 (0.53-1.65)	>.99
Symptom remission at 4 wk vs baseline (n = 57)^e	8/28 (28)	5/29 (17)	1.35 (0.72-2.20)	.36
Symptom remission at 6 wk vs baseline (n = 51)	7/26 (27)	5/25 (20)	1.19 (0.61-2.00)	.74
Symptom remission at 3 mo vs baseline (n = 47)	11/24 (46)	3/23 (13)	1.99 (1.16-3.34)	.02

Abbreviations: NSA, nonspecific auricular acupuncture; RR, risk ratio; SA, specific auricular acupuncture.

^{^a}

Effect size was calculated as RR for dichotomous data.

^{^b}

Statistical significance was calculated with Fisher exact test.

^{^c}

The primary outcome (improvement in depression symptoms) was defined as a reduction of 50% or more from baseline Patient Health Questionnaire-9 (PHQ-9) scores. The number of cases and proportions are based on observed data.

^{^d}

Depressive symptoms measured by PHQ-9 scores range from 0 (least) to 27 (greatest) symptom burden.

^{^e}

Participants who achieved a score less than 5 on the PHQ-9, indicating symptom remission.